Subscribe to receive updates
News Company Updates
Invenra To Feature Cancer Patient Art in Upcoming Antibody Therapy Development Project
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development
Invenra Highlights Exelixis’ Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors
Invenra Launches T-Body™ Trispecific Platform to Advance Next-Generation Therapeutic Antibodies
Invenra Launches B-Body Express™ Service, Enabling Rapid Access to its Premier B-Body® Bispecific Antibody Platform
Stay in the loop Subscribe to the Invenra Newsletter
Get new resources, insights, and platform updates right in your inbox. Unsubscribe anytime.
Only a few emails per month. No spam.